Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: Akt Inhibitor MK2206|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study
Sponsor: National Cancer Institute (NCI)